Maxcyte (MXCT) Assets (2020 - 2026)

Maxcyte (MXCT) has reported Assets for 7 consecutive years, with $184.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 15.96% year-over-year to $184.7 million in Q2 2026; TTM through Jun 2026 was $184.7 million, a 15.96% decrease from a year earlier, with the FY2025 full-year figure at $202.5 million, down 15.44% from the prior year.
• Assets was $184.7 million for Q2 2026 at Maxcyte, down from $194.5 million in the prior quarter.
• Over five years, Assets peaked at $291.0 million in Q1 2022 and troughed at $184.7 million in Q2 2026.
• A 5-year average of $249.1 million and a median of $254.7 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets surged 211.1% in 2022 and retreated 15.96% in 2026, its largest moves.
• Over 5 years, Assets stood at $286.7 million in 2022, then dropped by 6.41% to $268.3 million in 2023, then fell by 10.74% to $239.5 million in 2024, then retreated by 15.44% to $202.5 million in 2025, then fell by 8.81% to $184.7 million in 2026.
• The last three Assets figures came in at $184.7 million (Q2 2026), $194.5 million (Q1 2026), and $202.5 million (Q4 2025), per Business Quant data.